SEARCH:   Advanced

Blood, 29 October 2009, Vol. 114, No. 18, pp. 3742-3747. Prepublished online as a Blood First Edition Paper on August 28, 2009; DOI 10.1182/blood-2009-06-227330. This Article Full Text (PDF) All Versions of this Article: blood-2009-06-227330v1 114/18/3742    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bartolucci, P. Articles by Godeau, B. Search for Related Content PubMed PubMed Citation Articles by Bartolucci, P. Articles by Godeau, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 12, 2009 Accepted August 5, 2009 A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults Pablo Bartolucci, Tony El Murr, Francoise Roudot-Thoraval, Anoosha Habibi, Aline Santin, Bertrand Renaud, Violaine Noel, Marc Michel, Dora Bachir, Frederic Galacteros, and Bertrand Godeau* Service de Medecine Interne, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris, Universite Paris 12, Creteil, France Service d'Epidemiologie, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris, Universite Paris 12, Creteil, France Service de Reference de la Drepanocytose, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris, Universite Paris 12, Creteil, France Service d'Accueil des Urgences, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris, Universite Paris 12, Creteil, France * Corresponding author; email: bertrand.godeau{at}hmn.aphp.fr. Vaso-occlusive crisis (VOC) is the primary cause of hospitalization of patients with sickle-cell disease. Treatment mainly consists of intravenous morphine, which has many dose-related side effects. Nonsteroidal antiinflammatory drugs have been proposed to provide pain relief and decrease the need for opioids. Nevertheless, only a few underpowered trials of NSAID for sickle-cell VOC have been conducted and conflicting results were reported. We conducted a phase 3, double-blind, randomized, placebo-controlled trial with ketoprofen (300 mg/day for 5 days), a nonselective cyclooxygenase inhibitor, for severe VOC in adults. A total of 66 VOC episodes were included. The primary efficacy outcome was VOC duration. The secondary end points were morphine consumption, pain relief and treatment failure. Seven VOC episodes in each group were excluded from the analysis because of treatment failures. No significant between-group differences were observed for the primary outcome or the secondary end points. Thus, although ketoprofen was well-tolerated, it had no significant efficacy as treatment of VOC requiring hospitalization. These findings argue against its systematic use in this setting. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020